Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023
-
Patria Investments Completes Acquisition of Private Equity Solutions Business from abrdn and Expands Its Global Private Markets Capabilities
-
Immutep Quarterly Activities Report Q3 FY24
-
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
-
FuelCell Energy Announces Debt Financing for Derby Power Projects
-
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
-
Monarch Private Capital Finances Historic Rehabilitation of Iowa Mutual Insurance Building
-
Dayforce Appoints Amy Cappellanti-Wolf as EVP and Chief People Officer
-
Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperp
-
Corcept Completes Enrollment in Phase 4 CATALYST Trial
-
STACK Infrastructure Expands Texas Footprint with a New 220MW Flagship South Dallas Campus
-
Kratos Defense & Security Solutions Schedules First Quarter 2024 Earnings Conference Call for Tuesday, May 7th
-
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
-
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
-
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
-
TX RAIL PRODUCTS, INC. REPORTS SECOND QUARTER RESULTS FOR 2024 FISCAL YEAR
-
Sensei Labs Launches Harmony – the World’s First Enterprise Transformation AI
-
Vortex Energy’s Collaboration with the University of Alberta Receives Alberta Innovates Funding
-
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
-
Esperion to Participate in Upcoming May Investor Conferences
-
Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
-
Issue of Supplementary Prospectus
-
Spryker Opens its Platform and Ushers in a New Era of Ecosystem-Driven Innovation
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
THE BOARD OF DIRECTORS OF MARTELA CORPORATION RESOLVED ON A DIRECTED SHARE ISSUE FOR THE GROUP’S KEY EMPLOYEES AND ON FINANCING THE SHARE ACQUISITIONS
-
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting
-
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
-
KANZHUN LIMITED Releases 2023 Environmental, Social and Governance Report
-
Verde AgriTech ranks in Top 100 Teams in XPRIZE Carbon Removal Competition
-
MicroPets, A Journey of Redemption Led by Jessus Zambrano
-
Alice-SES Spearheads a Green Revolution in Finance: Investing with a Conscience
-
Invesco Ltd: Form 8.3 - BHP Group Ltd.
-
NowVertical Group Announces Delay in Annual Filings
-
Invesco Ltd: Form 8.3 - Anglo American PLC Public dealing disclosure
-
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
-
KANZHUN LIMITED Files Its Annual Report on Form 20-F
-
Heartland Financial USA, Inc. ("HTLF") Reports Quarterly Results as of March 31, 2024
-
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
-
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
-
UMB Announces Agreement to Acquire Heartland Financial
-
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
-
Heartland Financial USA, Inc. ("HTLF") Reports Quarterly Results as of March 31, 2024
-
Streamline Health® Expands eValuator™ Footprint With Existing Client
-
Dragonfly Energy to Report First Quarter 2024 Financial and Operational Results on May 14, 2024
-
Beji Varghese Joins FTI Consulting’s Financial Services Practice in Charlotte
-
OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rea
-
Form 8.3 - [LOK'N STORE GROUP PLC - 26 04 2024] - (CGWL)
-
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme
-
Bullet Blockchain Announces 2023 Financial Results
-
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
